Form 4: Ionis EVP C. Frank Bennett Executes Stock Option, Sells Shares

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock on August 18, 2025, according to a Form 4 filing.

Summary

• On August 18, 2025, C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, exercised a non-qualified stock option for 10,000 shares at a price of $32.60.
• Simultaneously, Bennett sold 10,000 shares of Ionis Pharmaceuticals common stock at a weighted average price of $43.9776, with prices ranging from $43.75 to $44.25.
• Following these transactions, Bennett directly owns 93,466 shares of Ionis Pharmaceuticals common stock and 18,869 derivative securities.

Sentiment

Score: 5

Explanation: Neutral. The filing represents a routine transaction (exercise of options and sale of shares under a pre-existing plan) with no explicit positive or negative implications.

Positives

• Executive exercising stock options indicates confidence in the company.
• Sale of shares was executed under a pre-arranged Rule 10b5-1 trading plan, suggesting an orderly and planned transaction.

Negatives

• Sale of 10,000 shares by a high-ranking executive could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence, although this sale was pre-planned.
• Fluctuations in Ionis Pharmaceuticals' stock price could impact the value of remaining holdings.

Future Outlook

The filing does not contain explicit forward-looking statements. However, the executive's continued holdings suggest a long-term interest in the company's performance.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are closely watched by investors for signals about company performance and management confidence. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on inside information.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are standard across the pharmaceutical industry. Companies like Alnylam Pharmaceuticals, Biogen, and Moderna also utilize stock options as part of their executive compensation packages.
• The use of Rule 10b5-1 trading plans is a common practice among executives in publicly traded companies to manage their stock sales in compliance with insider trading regulations. Many executives at companies such as Alnylam Pharmaceuticals, Biogen, and Moderna use similar plans.

Stakeholder Impact

• Shareholders: The stock sale could have a minor, short-term impact on stock price.
• Employees: No direct impact on employees.
• Customers: No direct impact on customers.
• Suppliers: No direct impact on suppliers.
• Creditors: No direct impact on creditors.

Key Dates

Recommendation

The filing represents a routine transaction (exercise of options and sale of shares under a pre-existing plan) with no explicit positive or negative implications. The executive still holds a significant amount of shares.

Keywords

Ionis Pharmaceuticals, C. Frank Bennett, stock options, Form 4, executive stock sale, Rule 10b5-1, IONS